Translunar Access, an Alternative Worth Considering

Título original: Transulnar versus transradial access for coronary angiography or percutaneous coronary intervention: A meta-analysis of randomized controlled trials. Khagendra Dahal. Et al. Catheterization and cardiovascular Intervention 2016:87;857-865

Courtesy of Dr. Carlos Fava.

Transradial access site (TRA) has been shown beneficial over the femoral (TFA), but there is little information on translunar access (TUA) that could offer the same benefits as TFA with no need for femoral cross-over.

5 randomized studies were included with a total 2744 patients undergoing coronary catheterization vs PCI. 1384 of these patients used TUA and 1360, TRA.

Follow up was at 30 days and one year.

MACE was similar between access sites (3.1% vs. 3.5%; RR 0.87, CI 95 0.56 to 1.36; p=0.5), There was no difference in access site related complications (14.9% vs. 15.4%; RR 0.92 (0.67-1.27); p=0.62) neither were there differences in spasm or occlusion rates. The presence of pseudoaneurysms, fistula or transradial /translunar nerve injury was similar and very low in both groups. TUA presented higher cross-over rate and number of punctures than TRA (14% vs. 3.8% p=0.003 and 1.57 vs. 1.4 p=0.0002 respectively) with no difference in access time, fluoroscopy time or contrast volume.

Conclusion
In patients that require coronary catheterization or PCI, translunar and transradial access sites have similar efficacy and safety except for a higher rate of punctures and femoral cross-over with TUA.

Editorial Comment
This analysis is very promising since it gives us the opportunity to count with another access site to do our procedures as safely and effectively as with TRA.

The higher number of punctures and cross-over may be related to the little use of this access site and the necessary learning curve, as was initially with TRA:

Courtesy of Dr. Carlos Fava.
Interventional Cardiologist
Favaloro Foundation – Buenos Aires

More articles by this author

CRT 2026 | CUT-DRESS Trial: Lesion Preparation with Cutting Balloon

In-stent restenosis (ISR) continues to represent a relevant clinical challenge in contemporary coronary angioplasty practice. Despite advances in drug-eluting stents, neointimal hyperplasia and suboptimal...

CRT 2026 | Clopidogrel vs Aspirin as Long-Term Monotherapy After Coronary Angioplasty

The use of aspirin as chronic antiplatelet therapy after percutaneous coronary intervention (PCI) has historically been the standard recommended by international guidelines. However, recent...

Bioresorbable devices vs DES in patients at high risk of restenosis. Seven-year follow-up of the COMPARE-ABSORB trial

Studies with second-generation drug-eluting stents (DES) have shown that the rate of target lesion failure (TLF) increases linearly up to 5–10 years of follow-up,...

Sheathless Femoral Impella: A New Strategy to Reduce Vascular Complications in High-Risk PCI?

Patients with complex coronary artery disease or cardiogenic shock undergoing percutaneous coronary intervention (PCI) may benefit from the hemodynamic support provided by percutaneous ventricular...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

CRT 2026 | TAVI-CLOSE Trial: Dual Suture vs Suture + Plug for Vascular Closure After Transfemoral TAVI

The transfemoral approach is the predominant strategy for transcatheter aortic valve implantation (TAVI). Although vascular complications are currently less frequent, they remain relevant determinants...

CRT 2026 | NAVITOR IDE: Hemodynamic Outcomes and 5-Year Durability of an Intra-Annular Self-Expanding Transcatheter Aortic Valve

As TAVI expands into younger populations and patients with lower surgical risk, prosthesis durability has become a key aspect of long-term management. The NAVITOR...

CRT 2026 | CUT-DRESS Trial: Lesion Preparation with Cutting Balloon

In-stent restenosis (ISR) continues to represent a relevant clinical challenge in contemporary coronary angioplasty practice. Despite advances in drug-eluting stents, neointimal hyperplasia and suboptimal...